Skip to content
Seqlense EUR-Lex

Commission Decision of 05/10/2017 declaring a concentration to be compatible with the common market (Case No COMP/M.8613 - KONICA MINOLTA / INNOVATION NETWORK CORPORATION OF JAPAN / AMBRY GENETICS) according to Council Regulation (EC) No 139/2004 (Only the English text is authentic)

CELEX
32017M8613
Document type
DEC_ENTSCHEID
Sector
Legislation
Date of document
2017-10-05
In force since
2017-10-05
Status
In force

Text

This document has no article-level structure in its source. Full text below.

m8613.docx EUROPEAN COMMISSION Brussels, 5.10.2017 C(2017) 6850 To the notifying parties: Subject : Case M.8613 - KONICA MINOLTA / INNOVATION NETWORK CORPORATION OF JAPAN / AMBRY GENETICS Commission decision pursuant to Article 6(1)(b) of Council Regulation (EC) No 139/2004 1 and Article 57 of the Agreement on the European Economic Area 2 Dear Sir or Madam, 1. On 01 September 2017 , the European Commission received notification of a proposed concentration pursuant to Article 4 of the Merger Regulation by which Konica Minolta, Inc. ("KM", Japan) and Innovation Network Corporation of Japan ("INCJ", Japan) indirectly acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of Ambry Genetics Corp ("AG" , USA) .

The concentration is accomplished by way of purchase of shares . 3 2. The business activities of the undertakings concerned are: - for KM: a technology company specializing in imaging products, data analysis optics and nano -fabrication. In this respect, KM develops and manufactures a wide range of hardware and software products that offer solutions to businesses. KM is active in 150 countries, across Europe, USA, Japan, China, Asia and other countries. - for INCJ : a public-private partnership of the Japanese Gover nment and 26 private companies. INCJ pursues investment activities by providing financial, technological and management support to next generation businesses.

It provides risk capital over the medium to long term to innovative enterprises with a growth potential that brings a value to society. - for AG : a healthcare company based in the US. It provides genetic laboratory testing services and is active in related genetic research activities. AG operates in California and focuses its business on the US and Canada with negligible activities in the EU. 3. After examination of the notification, the European Commission has concluded that the notified operation falls within the scope of the Merger Regulation and of paragraph 5 ( a ) and ( b ) of the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 .

4 4. For the reasons set out in the Notice on a simplified procedure, the European Commission has decided not to oppose the notified operation and to declare it compatible with the internal market and with the EEA Agreement. This decision is adopted in application of Article 6(1)(b) of the Merger Regulation and Article 57 of the EEA Agreement . For the Commission (S igned) Johannes LAITENBERGER Director - General (1) OJ L 24, 29.1.2004, p. 1 ( the ' Merger Regulation ' ). With effect from 1 December 2009, the Treaty on the Functioning of the European Union ( ' TFEU ' ) has introduced certain changes, such as the replacement of ' Community ' by ' Union ' and ' common market ' by ' internal market ' .

The terminology of the TFEU will be used throughout this decision. (2) OJ L 1, 3.1.1994, p. 3 ( the ' EEA Agreement ' ). (3) Publication in the Official Journal of the European Union No C 29 9 , 09.9.2 017 , p. 4 . (4) OJ C 366, 14.12.2013, p. 5 .

Relations

What this act cites, and what cites it.

Show relations

Versions

Point-in-time consolidated versions of this act.

Show versions